A Phase 2 interventional study of Minocycline and Hypochlorous Acid in Pancreatic Cancer and Skin Toxicities, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Memorial Sloan Kettering Cancer Center · Phase 2, Interventional, and Treatment
The researchers are doing this study to find out whether the combination of ivermectin and standard of care prophylaxis (SOCP; drugs given to prevent the development of a disease or condition) is an effective treatment approach for people with skin side effects caused by daraxonrasib treatment (daraxonrasib-induced skin toxicity). The researchers will compare the combination of ivermectin and SOCP with SOCP alone to see which treatment approach is more effective. The researchers will also look at how the study treatments impact participants' quality of life. The researchers will measure quality of life by having participants complete questionnaires.
3,311 studies on the registry are indexed under Pancreatic Neoplasms; 910 are open to participants now.
This study's planned enrollment of 122 is above the median of 46 across 2,480 interventional studies indexed under Pancreatic Neoplasms.
Browse Pancreatic Neoplasms studies →Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,959 studies on the registry; 325 are open to participants now.
Of its 132 completed or terminated interventional studies of FDA-regulated products, 68 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Minocycline Face: Hypochlorous acid solution Face: Hydrocortisone Trunk: Triamcinolone Scalp: Clobetasol propionate Photoprotection: Broad-spectrum sunscreen
Drug: Minocycline · Drug: Hypochlorous Acid · Drug: Hydrocortison cream · Drug: Triamcinolone (TAC) 0.1% cream · Drug: Clobetasol · Other: Photoprotection
Ivermectin 200mcg/kg orally weekly PLUS SOCP above as in Arm A
Drug: Minocycline · Drug: Hypochlorous Acid · Drug: Hydrocortison cream · Drug: Triamcinolone (TAC) 0.1% cream · Drug: Clobetasol · Other: Photoprotection · Drug: Ivermectin
Minocycline 100mg PO twice daily (or doxycycline alternative)
Face: Hypochlorous acid solution applied every morning
Face: Hydrocortisone 2.5% cream (or equivalent) applied twice daily
Trunk: Triamcinolone 0.1% cream (or equivalent) applied twice daily
Scalp: Clobetasol propionate 0.05% solution (or equivalent) applied twice daily
Broad-spectrum sunscreen (SPF 30 or higher) applied daily to sun- exposed areas
Ivermectin 200mcg/kg orally weekly PLUS
pustular drug eruption assessed
using the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0. Rash severity will be categorized into four ordered levels (grade 0, grade 1, grade 2, and grade 3), where lower grades indicate less severe disease involvement.
Time frame: Day 56 ± 3 days
Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Started Oct 2026 (actual). Primary completion is estimated for Oct 2028, 24 months after the start.
Of 297 non-industry phase 2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 80. This study's planned 24 months is below that.
Counting every sponsor, half of 364 studies reached it within 57 months; a quarter within 34 and three quarters within 80.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivermectin
Memorial Sloan Kettering Cancer Center →